Literature DB >> 18325779

Involvement of subtype 1 metabotropic glutamate receptors in apoptosis and caspase-7 over-expression in spinal cord of neuropathic rats.

Dario Siniscalco1, Catia Giordano, Carlo Fuccio, Livio Luongo, Franca Ferraraccio, Francesca Rossi, Vito de Novellis, Kevin A Roth, Sabatino Maione.   

Abstract

The effect of the non-selective, 1-aminoindan-1,5-dicarboxylic acid (AIDA), and selective (3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl) methanone (JNJ16259685), metabotropic glutamate subtype 1 (mGlu1) receptor antagonists, on rat sciatic nerve chronic constrictive injury (CCI)-induced hyperalgesia, allodynia, spinal dorsal horn apoptosis, and gliosis was examined at 3 and 7 days post-injury. RT-PCR analysis showed increased expression of bax, apoptotic protease-activating factor-1 (apaf-1), nestin, GFAP, and caspase-7 mRNA in the dorsal horn spinal cord by 3 days post-CCI. At 7 days post-CCI, only over-expression of bcl-2, nestin and GFAP mRNA was observed. Administration of AIDA reduced thermal hyperalgesia and mechanical allodynia at 3 and 7 days post-CCI; administration of JNJ16259685 reduced thermal hyperalgesia at 3 and 7 days post-CCI, but not mechanical allodynia. AIDA decreased the mRNA levels of bax, apaf-1, GFAP and caspase-7 genes. JNJ16259685 increased the mRNA levels of bcl-2 and GFAP gene, and decreased APAF-1 and caspases-7 genes. Inhibiting mGlu1 receptors also reduced TUNEL-positive profiles and immunohistochemical reactivity for caspase-7. We report here that despite inhibiting CCI-induced over-expression of pro-apoptotic genes in the spinal cord dorsal horn, the selective mGlu1 receptor antagonist JNJ16259685 exerted only a slight and transient allodynic effect. Moreover, JNJ16259685, but not the non-selective AIDA, increased astrogliosis which may account for its decreased analgesic efficacy. This study provides evidence that the contemporary and partial blockade of group I and likely ionotropic glutamate receptors may be a more suitable therapy than selective blockade of mGlu1 subtype receptors condition to decrease neuropathic pain symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18325779      PMCID: PMC2424141          DOI: 10.1016/j.phrs.2008.01.007

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  75 in total

1.  Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection, and strychnine.

Authors:  Tomosada Sugimoto; Gary J Bennett; Keith C Kajander
Journal:  Pain       Date:  1990-08       Impact factor: 6.961

2.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.

Authors:  C Stadelmann; T L Deckwerth; A Srinivasan; C Bancher; W Brück; K Jellinger; H Lassmann
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

3.  Group I metabotropic glutamate receptor antagonists block secondary thermal hyperalgesia in rats with knee joint inflammation.

Authors:  Liping Zhang; Ying Lu; Ying Chen; Karin N Westlund
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

4.  Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.

Authors:  X Liu; C N Kim; J Yang; R Jemmerson; X Wang
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

5.  Prostaglandin E1 prevents apoptotic cell death in superficial dorsal horn of rat spinal cord.

Authors:  T Kawamura; T Akira; M Watanabe; Y Kagitani
Journal:  Neuropharmacology       Date:  1997-08       Impact factor: 5.250

6.  Involvement of metabotropic glutamate receptors in excitatory amino acid and GABA release following spinal cord injury in rat.

Authors:  C D Mills; G Y Xu; D J McAdoo; C E Hulsebosch
Journal:  J Neurochem       Date:  2001-11       Impact factor: 5.372

7.  Role of caspase-3 in ethanol-induced developmental neurodegeneration.

Authors:  Chainllie Young; Kevin A Roth; Barbara J Klocke; Tim West; David M Holtzman; Joann Labruyere; Yue-Qin Qin; Krikor Dikranian; John W Olney
Journal:  Neurobiol Dis       Date:  2005-05-31       Impact factor: 5.996

8.  Group I metabotropic glutamate receptors in spinal cord injury: roles in neuroprotection and the development of chronic central pain.

Authors:  Charles D Mills; Kathia M Johnson; Claire E Hulsebosch
Journal:  J Neurotrauma       Date:  2002-01       Impact factor: 5.269

9.  The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist.

Authors:  A Kłodzińska; E Tatarczyńska; K Stachowicz; E Chojnacka-Wójcik
Journal:  J Physiol Pharmacol       Date:  2004-03       Impact factor: 3.011

Review 10.  ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4.

Authors:  Kazuhide Inoue; Makoto Tsuda; Schuichi Koizumi
Journal:  J Pharmacol Sci       Date:  2004-02       Impact factor: 3.337

View more
  11 in total

1.  Selective mGluR1 antagonist EMQMCM inhibits the kainate-induced excitotoxicity in primary neuronal cultures and in the rat hippocampus.

Authors:  Maria Śmiałowska; Krystyna Gołembiowska; Małgorzata Kajta; Barbara Zięba; Anna Dziubina; Helena Domin
Journal:  Neurotox Res       Date:  2011-12-06       Impact factor: 3.911

2.  Cycling exercise affects the expression of apoptosis-associated microRNAs after spinal cord injury in rats.

Authors:  Gang Liu; Benjamin E Keeler; Victoria Zhukareva; John D Houlé
Journal:  Exp Neurol       Date:  2010-09-16       Impact factor: 5.330

3.  TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception.

Authors:  Catia Giordano; Luigia Cristino; Livio Luongo; Dario Siniscalco; Stefania Petrosino; Fabiana Piscitelli; Ida Marabese; Luisa Gatta; Francesca Rossi; Roberta Imperatore; Enza Palazzo; Vito de Novellis; Vincenzo Di Marzo; Sabatino Maione
Journal:  Cereb Cortex       Date:  2011-12-01       Impact factor: 5.357

4.  The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients.

Authors:  Dario Siniscalco; Anna Sapone; Catia Giordano; Alessandra Cirillo; Vito de Novellis; Laura de Magistris; Francesco Rossi; Alessio Fasano; Sabatino Maione; Nicola Antonucci
Journal:  J Autism Dev Disord       Date:  2012-07

5.  Metabotropic glutamate antagonists alone and in combination with morphine: comparison across two models of acute pain and a model of persistent, inflammatory pain.

Authors:  Mitchell J Picker; Dana Daugherty; Fredrick E Henry; Laurence L Miller; Linda A Dykstra
Journal:  Behav Pharmacol       Date:  2011-12       Impact factor: 2.293

Review 6.  Central sensitization: a generator of pain hypersensitivity by central neural plasticity.

Authors:  Alban Latremoliere; Clifford J Woolf
Journal:  J Pain       Date:  2009-09       Impact factor: 5.820

7.  Role of neurotrophins in neuropathic pain.

Authors:  Dario Siniscalco; Catia Giordano; Francesco Rossi; Sabatino Maione; Vito de Novellis
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

8.  Ceftriaxone, a beta-lactam antibiotic, modulates apoptosis pathways and oxidative stress in a rat model of neuropathic pain.

Authors:  Bahareh Amin; Valiollah Hajhashemi; Khalil Abnous; Hossein Hosseinzadeh
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411

9.  Fibroblast Growth Factor 1 Gene-Transfected Adipose-Derived Mesenchymal Stem Cells Modulate Apoptosis And Inflammation In The Chronic Constriction Injury Model of Neuropathic Pain.

Authors:  Fatemeh Forouzanfar; Hamid R Sadeghnia; Seyed Javad Hoseini; Ahmad Ghorbani; Hamed Ghazavi; Faezeh Ghasemi; Hossein Hosseinzadeh
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

Review 10.  Inflammation and Neuro-Immune Dysregulations in Autism Spectrum Disorders.

Authors:  Dario Siniscalco; Stephen Schultz; Anna Lisa Brigida; Nicola Antonucci
Journal:  Pharmaceuticals (Basel)       Date:  2018-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.